NORTON, Mass. - What the first week of the FedEx Cup playoffs revealed was it is not the best time to be one of the biggest names in golf.
With the exception of Dustin Johnson, the runaway winner at The Northern Trust, the first event of the PGA Tour's FedEx Cup playoffs, some of the sport's brightest stars have looked a bit lost.
Sure, Tiger Woods closed with a 66, including a four-birdie run to start his final round, but all it did was mask three uneven days that had him in a spot he never wants to be in -- playing early in the morning on the weekend of a tournament as nothing more than an afterthought.
Rory McIlroy, who played poorly enough to be Woods' early morning playing partner on the weekend, had no other choice but to make a joke or two about his own mediocrity lately when it was all over. More telling was that he feels at times he is simply going through the motions.
Brooks Koepka didn't even make it to the first tee, withdrawing before the event began because his bad knee isn't getting any better.
Jordan Spieth and Phil Mickelson didn't make the cut, placing them outside the top 70, which is required to gain entry into next week's BMW Championship, the second stop of the FedEx Cup playoffs.
He admitted Sunday that life without fans has been a difficult adjustment. He has always fed off the energy of the galleries that engulfed him -- and used it as an advantage over opponents who were shell-shocked by all the people and all the commotion.
But the silence seems to be a secondary problem for Woods. The inconsistency in his game remains the central issue. At The Northern Trust, he struggled at times with his putting; during Saturday's ugly 2-over 73, he missed six putts inside 10 feet. Until Sunday, he was again off with his short irons, regularly leaving lengthy birdie putts instead of medium-to-short range opportunities. His average distance from the hole on approach was just under 37 feet, which doesn't provide a ton of realistic birdie chances.
"Every day is different," he said. "That's golf. Shot-to-shot is different. That's the ebb and flow of playing golf."
He has played three events since golf's return from a three-month shutdown because of the coronavirus pandemic. He was a non-factor at both the Memorial and PGA Championship, finished tied for 37th and 40th. This week, at the Northern Trust, he had a strong opening round, then faded on Friday and Saturday. He's committed to this week's BMW Championship but hasn't earned a spot in the season-ending Tour Championship. And in this new, condensed schedule, the U.S. Open, the year's second major, is lurking right around the corner, set to begin Sept. 17 at ultra-difficult Winged Foot.
"This is going to be a long haul," he said.
Sure, the state of McIlroy's game is unsettling.
"If you need anyone to shoot even to 2-under for a week, I'm your man," he joked after finishing the week at, you guessed it, 2 under. "That's sort of what I've done the last few weeks. Everything is just a little off."
More concerning than his game might be his mindset.
"This is going to sound really bad, but I feel like the last few weeks, I've just been going through the motions," he said. "I want to get an intensity and some sort of fire, but I just haven't been able to. And look, that's partly to do with the atmosphere and partly to do with how I'm playing. I'm not inspiring myself, and I'm trying to get inspiration from outside sources to get something going."
On Saturday, with Woods, he started his round birdie/triple bogey/birdie. As he walked to the fourth tee he chuckled, "Yeah, 3-8-2 is a good area code." He was asked, in this time of playing tournaments without crowds and largely in silence, what the difference is now between a birdie and triple bogey?
"Honestly, not that much," he admitted. "It's not that much. Sometimes I come off a green and make a birdie, and I'm sort of -- you know, you're sort of laughing coming off a hole that you've just messed up, and you make a birdie, and it's sort of almost a more negative emotion in some ways. It's weird. It's very strange."
With two more playoff events and two more majors still on the 2020 calendar, how does he fix it?
"Do you go on YouTube and look at past successes do you give yourself something to sort of think about, a mantra as you go around?" he wondered. "There's different ways to do it. You know, what's always sort of done well with me is a bet or a game or a play for something. That sometimes gets something out of me. Maybe that's the strategy. I do that in practice rounds sometimes with [caddie and close friend] Harry [Diamond]. We make a lot of bets, and I try to shoot scores and try to win dinner or whatever it is. Maybe that's it. We're playing in the FedEx Cup [playoffs]. There's a lot of incentive here to play well. It's just trying to get it out of you."
McIlroy was on a roll before golf stopped in March. In the six events he played before the sport started at the Players Championship, McIlroy had not finished worse than a tie for fifth, and that included a win at the WCG-HSBC Champions. Since the return, has just one top-30 finish, a tie for 11th at the Travelers Championship.
"Yeah, it's just been a bit of a struggle," he said.
On Friday, as his round and season concluded, Jordan Spieth walked quickly off the 18th green at TPC Boston, never picking his head up as he headed toward the clubhouse. He had missed his second cut in six events, this one following a T-71 finish at the PGA Championship and a T-72 at the Wyndham Championship. He's had just one top-20 since a T-10 at the Charles Schwab Challenge, the first event after the break.
I'm a little uncertain. Like it feels pretty good, not great, but good enough to be able to compete," he said after the Wyndham Championship.
The missed cut at The Northern Trust meant he would not qualify for next week's BMW Championship, marking the first time in his career he did not advance to the second stage of the FedEx Cup playoffs. He hasn't made it to the season-ending Tour Championship since 2017. He hasn't won an event since the 2017 Open at Royal Birkdale, a stretch of 69 events.
"I'll keep trucking, I'll keep working hard," he said.
As long as his knee is up to it, the next time we'll see Koepka is at the U.S. Open, where he will try to win that major for the third time in four years. It's been an up-and-down year for the four-time major winner, who had a stem cell procedure on his left knee after last year's Tour Championship then re-aggravated when he slipped during an event in South Korea in October, which required him to sit out until January.
Since then, he's had just two top-10s, missed four cuts and had to withdraw from two events, one because of injury, one because his caddie, Ricky Elliott, tested positive for COVID-19.
Earlier this month, in search of his third consecutive PGA Championship, he entered the final round tied for fourth, just 2 shots off the lead. He faded on Sunday, shooting 74 to tie for 29th. The next week he missed the cut at the Wyndham Championship.
"Brooks is one of the biggest names in the game. We've all seen his physical struggles since last year," McIlroy said earlier this week. "It's maybe never a good time, but it's a better time than any other time to get it right. Take a few weeks off, try to get himself ready for the U.S. Open, and then the Masters coming up [in November]. I think it's smart on his part to do that and hopefully comes back healthy and comes back ready to play."
Like Spieth, Mickelson missed the cut and didn't qualify for the BMW Championship. So to get some work in before returning to what the site of one of his most painful major championship disappointments -- Winged Foot, site of this year's U.S. Open -- he needed to find a place to play.
Enter the PGA Tour Champions, the over-50 circuit that has an event this week in the Ozarks.
"I've been playing well and I want to play," he said. "I wish I was playing in Chicago next week but excited to play my first Champions event."
Mickelson, who turned 50 in June, has one top-20 finish and two missed cuts since golf's return. He had been reluctant to head over to the Champions Tour, making it clear he thinks he can still play -- and win -- on the PGA Tour.
"When I stop hitting bombs, I'll play the Champions Tour, but I'm hitting some crazy bombs right now," he joked in January.
Read more from the original source:
Tiger Woods, Rory McIlroy and more -- This isn't the best time for some of the PGA Tour's biggest names - ESPN
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020